Ignite Creation Date:
2024-05-06 @ 2:09 AM
Last Modification Date:
2024-10-26 @ 11:14 AM
Study NCT ID:
NCT01981486
Status:
WITHDRAWN
Last Update Posted:
2014-05-23
First Post:
2013-11-05
Brief Title:
A Study Of The Safety Tolerability And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase I Placebo Controlled Randomized Subject-And Investigator-Blind Sponsor-Open Multiple Ascending Dose Study To Evaluate The Safety Tolerability And Pharmacokinetics Of PF-05180999 In Healthy Adult Volunteers
Status:
WITHDRAWN
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
PF-05180999 is a novel phosphodiesterase-2 PDE2 inhibitor The purpose of this study is to evaluate the safety tolerability and pharmacokinetics of multiple doses of PF-05180999 administered twice daily over 14 days Exploratory measures of PDE2 inhibition will also be evaluated in blood and blister fluid
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None